New Haven biotech Alexion Pharmaceuticals Inc. will partner with a startup in the Netherlands on a new drug to treat degenerative brain disorders. Alexion on Monday announced a deal with ...

“ Our collaboration with Dicerna to discover and develop GalXC RNAi therapies, which have the potential to inhibit uncontrolled activation of the complement system in new ways, represents an exciting ...

Some of the greatest advancements in modern medicine started with a scientist taking a risk to boldly pursue new areas of research. For scientists at Alexion — a leading biotech company dedicated to ...

As Kira Pharma shepherds two more programs toward the clinic, the complement-focused biotech is bolstering its leadership team with a trio of biopharma veterans, including a pair of Alexion alums. Its ...

Most people are familiar with the immune system and its role in protecting against diseases and infection. But what about the complement system? The complement system is a foundational part of the ...

Alexion Pharmaceuticals will acquire New Haven-based pharmaceutical company Achillion Pharmaceuticals for an anticipated $930 million, the companies announced last week. The two companies develop rare ...

Two pioneers of the Elm City’s bioscience industry are about to become one. Alexion Pharmaceuticals Inc. said Wednesday morning it plans to acquire fellow New Haven-born drugmaker Achillion ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The bar for innovation has never been higher. Regardless of ...

For years, Alexion has been the only name in the game for a blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Now, a number of Big Pharmas want in, vying to show their candidates can go ...

The complement system is designed to kill pathogens through a signal cascade that results in cell lysis, removal of the pathogens through phagocytosis, and alerting other immune system cells to help ...

“Our collaboration with Dicerna to discover and develop GalXC RNAi therapies, which have the potential to inhibit uncontrolled activation of the complement system in new ways, represents an exciting ...